Ivabradine Zydus

Ivabradine, the active ingredient in Ivabradine Zydus, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradine Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions. - Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate without affecting contractility. - Heart failure with reduced ejection fraction (HFrEF): decreases heart rate to improve ventricular filling and functional capacity. - Symptomatic sinus tachycardia (off‑label in some regions): may be used to control elevated resting heart rate when other agents are unsuitable.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate slower than intended. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Nausea or gastrointestinal discomfort.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Persistent visual impairment. - Severe hypotension. - Allergic reactions such as rash or angioedema. - Myocardial ischemia exacerbation.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential risks. - Cardiac monitoring: assess resting heart rate and ECG prior to starting treatment. - Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses. - CYP3A4 inhibitors: consider dose reduction or increased monitoring. - Renal impairment: use with caution and monitor renal function. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine can interact with several medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma concentrations. - Verapamil or diltiazem: combined use can cause excessive bradycardia. - Other potent heart‑rate lowering agents (high‑dose beta‑blockers): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Drugs that prolong QT interval (certain antidepressants, antipsychotics): monitor ECG for arrhythmia risk. - Diuretics causing electrolyte shifts: watch for hypotension and electrolyte abnormalities.